Trevi Therapeutics Inc. (TRVI)
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General